<DOC>
	<DOCNO>NCT03054428</DOCNO>
	<brief_summary>To demonstrate efficacy dupilumab monotherapy patient ≥12 year &lt; 18 year age moderate-to-severe atopic dermatitis ( AD )</brief_summary>
	<brief_title>Efficacy Safety Dupilumab Patients ≥12 &lt; 18 Years Age , With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Skin Diseases , Eczematous</mesh_term>
	<criteria>Male female ≥12 &lt; 18 year age time screen visit Diagnosis AD accord American Academy Dermatology consensus criterion screen visit IGA ≥3 screen baseline visit EASI ≥16 screen baseline visit Baseline Pruritus Numerical Rating Scale ( NRS ) average score maximum itch intensity ≥4 ≥10 % body surface area ( BSA ) AD involvement screen baseline visit With documented recent history ( within 6 month screen visit ) inadequate response topical AD medication ( ) topical treatment medically inadvisable Participation prior dupilumab clinical study Treatment TCS topical calcineurin inhibitor ( TCI ) within 2 week baseline visit Having use immunosuppressive/immunomodulating drug within 4 week baseline visit Body weight &lt; 30 kg Baseline Active chronic acute infection require treatment systemic antibiotic , antiviral , antiprotozoal , antifungal within 2 week baseline visit Known suspect immunodeficiency , know history human immunodeficiency virus ( HIV ) infection HIV seropositivity screen visit , establish diagnosis HBV infection HBV seropositivity screening , establish diagnosis HCV infection HCV seropositivity screen History malignancy baseline visit Diagnosed active endoparasitic infection high risk infection Patient female pregnant , breastfeeding , plan become pregnant breastfeed study Patient female childbearing potential sexually active , unwilling use adequate method contraception throughout duration study 120 day last dose study drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>